Venous and arterial thrombosis associated with HIV infection

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 5, 2012, Pages 524-529

  Dentali, Francesco ^a   Nicolini, Eleonora ^a   Ageno, Walter ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

acquired immunodeficiency syndrome; arterial thrombosis; human immunodeficiency virus; venous thrombosis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GLUCOSE;

ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; GLUCOSE INTOLERANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTENSION; MORTALITY; OBESITY; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; BLOOD; METHODOLOGY; REVIEW; RISK FACTOR; THROMBOSIS; VIROLOGY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; RISK FACTORS; THROMBOSIS; VENOUS THROMBOSIS;

EID: 84860501218     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1306434     Document Type: Article

References (51)

1. Campsmith M. L., Rhodes P., Hall H. I., et al. HIV prevalence estimates-United States, 2006. MMWR: 2008; 57 1073 1076
2. Joint United Nations Programme on HIV/AIDS. Executive summary: 2008 report on the global AIDS epidemic. Available at: http://www.unaids.org/en. Accessed March 10, 2009
3. Palella F. J. Jr, Baker R. K., Moorman A. C., et al; HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr: 2006; 43 1 27 34 (Pubitemid 44306484)
4. Crum N. F., Riffenburgh R. H., Wegner S., et al. Triservice AIDS Clinical Consortium. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr: 2006; 41 2 194 200
5. Grinspoon S., Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med: 2005; 352 1 48 62 (Pubitemid 40075680)
6. Ross A. C., Rizk N., O'Riordan M. A., et al. Relationship between infiammatory markers, endothelial activation markers and carotid intima-media thickness in HIV-infected patients reciving antiretroviral therapy. Clin Infect Dis: 2009; 49 1119 1127
7. Vigouroux C., Maachi M., Nguyên T. H., et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS: 2003; 17 10 1503 1511 (Pubitemid 36900551)
8. Ho J. E., Hsue P. Y. Cardiovascular manifestations of HIV infection. Heart: 2009; 95 14 1193 1202
9. Hsue P. Y., Hunt P. W., Schnell A., et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS: 2009; 23 9 1059 1067
10. de Larrañaga G. F., Petroni A., Deluchi G., Alonso B. S., Benetucci J. A. Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus-1-infected patients. Blood Coagul Fibrinolysis: 2003; 14 1 15 18 (Pubitemid 36206717)
11. Klein S. K., Slim E. J., de Kruif M. D., et al. Is chronic HIV infection associated with venous thrombotic disease? A systematic review. Neth J Med: 2005; 63 4 129 136 (Pubitemid 40561527)
12. Kaplan R. C., Kingsley L. A., Sharrett A. R., et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis: 2007; 45 8 1074 1081 (Pubitemid 47580361)
13. Savès M., Chêne G., Ducimetière P., et al. French WHO MONICA Project and the APROCO (ANRS EP11) Study Group. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population.
14. Gritz E. R., Vidrine D. J., Lazev A. B., Amick B. C. III, Arduino R. C. Smoking behavior in a low-income multiethnic HIV/AIDS population. Nicotine Tob Res: 2004; 6 1 71 77 (Pubitemid 38372476)
15. Carr A., Samaras K., Thorisdottir A., Kaufmann G. R., Chisholm D. J., Cooper D. A. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet: 1999; 353 9170 2093 2099 (Pubitemid 29278477)
16. Brown T. T., Cole S. R., Li X., et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med: 2005; 165 10 1179 1184 (Pubitemid 40720744)
17. Grundy S. M., Cleeman J. I., Daniels S. R., et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation: 2005; 112 17 2735 2752 (Pubitemid 41532612)
18. Tebas P. Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options. J Acquir Immune Defic Syndr: 2008; 49 Suppl 2 S86 S92
19. Umeh O. C., Currier J. S. Lipids, metabolic syndrome and risk factors for future cardiovascular disease among HIV-infected patients. Current HIV/AIDS Rep: 2005; 2 132 139
20. Florescu D., Kotler D. P. Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients. Antivir Ther: 2007; 12 2 149 162 (Pubitemid 46569900)
21. Périard D., Telenti A., Sudre P., et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation: 1999; 100 7 700 705 (Pubitemid 29383638)
22. Gatell J., Squires K., Piliero P., et al. Atazanavir (BMS-232632): absence of serum lipid changes after 48 weeks of treatment in treatment-naïve HIV positive subjects. Antivir Ther: 2000; 6 Suppl 4 49S
23. Grinspoon S. K., Grunfeld C., Kotler D. P., et al. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation: 2008; 118 2 198 210
24. Grinspoon S. K. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med: 2005; 118 Suppl 2 23S 28S
25. El-Sadr W. M., Lundgren J. D., Neaton J. D., et al. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med: 2006; 355 22 2283 2296 (Pubitemid 44837777)
26. Hsue P. Y., Lo J. C., Franklin A., et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation: 2004; 109 1603 1608 (Pubitemid 38451715)
27. van Vonderen M. G., Smulders Y. M., Stehouwer C. D., et al. Carotid intima-media thickness and arterial stiffness in HIV-infected patients: the role of HIV, antiretroviral therapy, and lipodystrophy. J Acquir Immune Defic Syndr: 2009; 50 2 153 161
28. Maggi P., Serio G., Epifani G., et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS: 2000; 14 123 128
29. Currier J. S., Kendall M. A., Zackin R., et al. AACTG 5078 Study Team. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS: 2005; 19 9 927 933 (Pubitemid 40834935)
30. Depairon M., Chessex S., Sudre P., et al. Swiss HIV Cohort Study. Premature atherosclerosis in HIV-infected individuals-focus on protease inhibitor therapy. AIDS: 2001; 15 3 329 334 (Pubitemid 32163818)
31. Seminari E., Pan A., Voltini G., et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis: 2002; 162 2 433 438 (Pubitemid 34457950)
32. Hulten E., Mitchell J., Scally J., Gibbs B., Villines T. C. HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies. Heart: 2009; 95 22 1826 1835
33. Bozzette S. A., Ake C. F., Tam H. K., Chang S. W., Louis T. A. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med: 2003; 348 8 702 710 (Pubitemid 36237039)
34. Friis-Moller N., Weber R., Reiss P., et al. DAD study group. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS: 2003; 17 8 1179 1193 (Pubitemid 36667761)
35. Triant V. A., Lee H., Hadigan C., Grinspoon S. K. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab: 2007; 92 2506 2512 (Pubitemid 47037350)
36. Currier J. S., Taylor A., Boyd F., et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr: 2003; 33 4 506 512 (Pubitemid 36886080)
37. Choi A. I., Li Y., Deeks S. G., Grunfeld C., Volberding P. A., Shlipak M. G. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation: 2010; 121 5 651 658
38. Becker D. M., Saunders T. J., Wispelwey B., Schain D. C. Case report: venous thromboembolism in AIDS. Am J Med Sci: 1992; 303 6 395 397
39. Copur A. S., Smith P. R., Gomez V., Bergman M., Homel P. HIV infection is a risk factor for venous thromboembolism. AIDS Patient Care STDS: 2002; 16 5 205 209 (Pubitemid 34478160)
40. Micieli E., Dentali F., Giola M., Grossi P., Venco A., Ageno W. Venous and arterial thrombosis in patients with HIV infection. Blood Coagul Fibrinolysis: 2007; 18 3 259 263 (Pubitemid 46597399)
41. Laing R. BS, Brettle R. P., Leen C. LS. Venous thrombosis in HIV infection. Int J STD AIDS: 1996; 7 2 82 85 (Pubitemid 26128283)
42. Saif M. W., Bona R., Greenberg B. AIDS and thrombosis: retrospective study of 131 HIV-infected patients. AIDS Patient Care STDS: 2001; 15 6 311 320 (Pubitemid 32554157)
43. Lijfering W. M., Ten Kate M. K., Sprenger H. G., van der Meer J. Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy. J Thromb Haemost: 2006; 4 9 1928 1930 (Pubitemid 44226770)
44. Sullivan P. S., Dworkin M. S., Jones J. L., Hooper W. C. Epidemiology of thrombosis in HIV-infected individuals. The Adult/Adolescent Spectrum of HIV Disease Project. AIDS: 2000; 14 3 321 324 (Pubitemid 30132927)
45. Fultz S. L., McGinnis K. A., Skanderson M., Ragni M. V., Justice A. C. Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans. Am J Med: 2004; 116 6 420 423 (Pubitemid 38299488)
46. Matta F., Yaekoub A. Y., Stein P. D. Human immunodeficiency virus infection and risk of venous thromboembolism. Am J Med Sci: 2008; 336 5 402 406
47. Malek J., Rogers R., Kufera J., Hirshon J. M. Venous thromboembolic disease in the HIV-infected patient. Am J Emerg Med: 2011; 29 3 278 282
48. Dubé M. P., Stein J. H., Aberg J. A., et al. Adult AIDS Clinical Trials Group Cardiovascular Subcommittee; HIV Medical Association of the Infectious Disease Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis: 2003; 37 5 613 627 (Pubitemid 37100800)
49. Lundgren J. D., Battegay M., Behrens G., et al. EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med: 2008; 9 2 72 81 (Pubitemid 351232645)
50. Mancia G., De Backer G., Dominiczak A., et al. The task force for the management of arterial hypertension of the European Society of Hypertension; The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J: 2007; 28 1462 1536
51. Squizzato A., Galli M., Romualdi E., et al. Statins, fibrates, and venous thromboembolism: a meta-analysis. Eur Heart J: 2010; 31 10 1248 1256